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Diffuse large B-cell lymphoma (DLBCL) is the commonest lymphoma both in humans and in dogs. 1. Due 
to spontaneously high incidence, complex genetics interplay, aggressive clinical course, elevated 
frequency and the presence of an intact immune system, dogs with lymphoma are considered as an ideal 
comparative model for drug development for human lymphomas 1. The BCL2 inhibitor venetoclax and the 
BTK inhibitors ibrutinib and acalabrutinib are examples of drugs that benefited of such model 2-4. Clinical 
heterogeneity of canine DLBCL (cDLBCL) is known and early insights on its biologic and molecular 
mechanisms, revealing similarities with the human counterpart, have been reported, but a genomic 
characterization of this tumor has never been provided. Furthermore, a complete understanding of the 
molecular mechanisms driving cDLBCL pathogenesis is necessary to more accurately take advantage of 
this comparative model and, also, to improve the clinical outcome of the dogs. In this study, we report the 
first large integrated analysis with transcriptome sequencing, methylation genome wide analysis, copy 
number variation (CNV) analysis and clinical outcome in cDLBCLs to comprehensively define the 
molecular mechanisms of this tumor and to better define its use in comparative medicine. 
We first compared the transcriptome obtained via RNA-Seq in 50 cDLBCLs versus RNA-Seq data of 
normal follicular B-cells derived from lymph nodes of 11 healthy dogs (Online Supplementary Table S1; 
Online Supplementary Methods). Transcripts higher in cDLBCLs than in controls were significantly 
enriched of genes coding for proteins involved in the B-cell receptor (BCR), MYC signaling, 
PI3K/AKT/mTOR pathway, DNA replication, and cell cycle (Online Supplementary Figure S1). Genes 
coding for proteins involved in the NF-kB pathway (CD79, CD19, SYK, LYN, CARD11, BCL10, BTK, 
TRAF6, MYD88, NFKB2, TLR7, TLR9) were also differentially expressed (Figure 1). The aberrant 
expression of these genes might contribute to enhance proliferation and protection from apoptosis of B-
cells by stimulating NF-κB activity. A similar mechanism is described in human ABC-DLBCL, characterized 
by a constitutive activation of NF-κB due to mutations in multiple genes belonging to this pathway 
subgroup 5. These data fit with the reported frequent inactivation of the NF-κB negative regulator TRAF3 in 
canine B-cell lymphomas 6, and the anti-tumor activity of BTK inhibitors, specifically active in the human 
ABC DLBCL subtype and experimentally used in canine B-cell lymphomas 3, 4.  
The protein encoding gene LIN28B appeared as the most upregulated transcript in tumors. While LIN28B 
does not seem to be a relevant gene for human DLBCL, it is involved in the activation of the NF-kB 
pathway and of MYC in different human and mouse tumor models and its overexpression causes murine 
peripheral T-cell lymphomas 7. We took advantage of the CLBL-1 cell line, the only in vitro model available 
of cDLBCL, which showed a profile similar to cDLBCL clinical specimens, with LIN28B as the most 
overexpressed gene compared to normal lymph nodes (Online Supplementary Table S3). LIN28B 
silencing using LNA modified-siRNAs led to a reduction in the cell-proliferation compared to the negative 
control (Online Supplementary Figure S2), opening new therapeutic target perspectives at least in 
cDLBCL.  
The integration of CNVs data and transcriptome showed an association in 320 genes. A total of 239 genes 
were located in regions of gains and simultaneously overexpressed, while 81 genes were downregulated 
and mapped in regions of deletions (Online Supplementary Table S4). The gains of the entire Chr 13 and 
31 and losses of Chr 14 were the most frequent aberrations, occurring in >20% of the cases (Online 
Supplementary Figure S3). Survival analysis showed a trend for longer OS and EFS in dogs affected by 
this Chr 13 aberration versus the remaining animals (P=0.134). A series of additional CNVs, such as gains 
in Chr 4, 27 and loss in Chr 28, were observed in at least two dogs (Figure S2). 
A genome-wide NGS-based methylation analysis, previously never performed in canine lymphomas, 
identified differentially methylated regions (DMRs) between cDLBCLs and the normal follicular B-cells 
(Online Supplementary Table S4; Online Supplementary Figure S4-5). In accordance with RNA-Seq data, 
genes that presented a reduced degree of promoter methylation in cDLBCLs were enriched of transcripts 
involved in cytokine/cytokine receptor interaction, BCR and JAK/STAT signaling. Genes participating to 
calcium signaling, cytoskeleton, Hedgehog/Wnt signaling and metabolism more commonly presented an 
increased promoter methylation in neoplastic cells than in normal B-cells and were also down-regulated 
(Online Supplementary Table S4). In line with our previous study 8, the latter observed increased promoter 
methylation sustains the evaluation of hypomethylating agents in the treatment of cDLBCL.  
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Unsupervised clustering of RNA-Seq data separated cDLBCLs from normal follicular B-cells (Figure 2A) 
and identified two distinct subgroups within the tumors (Figure 2B). The two groups did not overlap with 
the human GCB and ABC DLBCL subtypes or the DLBCL consensus clusters 5, but they were associated 
with different OS (278 vs 150 days, P<0.01) and EFS (179 vs 113 days, n.s) (Figure 2C-D). Tumors 
belonging to the group with worse prognosis were characterized by a higher expression of transcripts 
coding for proteins involved in apoptosis, JAK/STAT signaling, microenvironment, inflammatory response 
and P53 pathway (Online Supplementary Table S5). In particular, dogs with the poorest outcome 
presented a signature largely defined by markers of T-cell-mediated immune responses, with a higher 
expression of transcripts involved in T-cells and macrophages regulation (CD163, CD96, PD-1, PDL-1, 
CTLA4, CD8a, CD4), as also shown by an enrichment of gene expression signatures of immune-inhibitory 
molecules (Online Supplementary Figure S6), and genes associated with ATP-binding cassette transporter. 
The two DLBCL clusters were also sustained by methylation and CNV differences (Online Supplementary 
Figure S7). Cases with inferior outcome presented a higher degree of promoter methylation (P<0.005), and 
a higher number of aberrations (P<0.01) compared to the remaining, but no equivalent to the human 9p24 
amplification associated with expression of PD-L1, which could be mainly sustained by the observed 
activation of JAK/STAT pathway.  
We first validated the pattern of expression of PDL-1, PD-1, CTLA-4 and CD5 by immunohistochemistry 
(Online Supplementary Figure S8). All the 25 samples belonging to the poor outcome group were strongly 
positive for PDL-1 and CTLA-4 (TPS higher than 50%), while cases of the other cluster were completely 
negative (n=5, 20%) or weakly positive (TPS between 1% and 40%; n=20, 80%). The same cases also 
presented a higher number of PD-1 and CD5 positive cells (higher or lower than 20 for HPF). We then 
analyzed an independent series of 44 cDLBCLs, all treated with CHOP plus vaccine 9. PDL-1 and PD-1 
stainings were positive in 21 (48%) and 25 cases (57%), respectively, and conferred inferior outcome 
(Figure 2E-F). CTLA-4 and CD5 expression occurred in 18 (41%) and 22 cases (50%) but were not 
associated with clinical outcome. In a multivariate analysis including bone marrow infiltration and 
substage, PD-L1 and PD-1 maintained their prognostic impact on OS, but not on EFS (Online 
Supplementary Table S6). The obtained results represent a strong basis towards the evaluation novel 
regimens based on immune-checkpoint inhibitors in canine lymphomas before moving to the human 
setting. Combination of immune checkpoint modulators with active vaccines 9 would be also worth of being 
explored. 
Transcriptome data suggested potential therapeutic implications. First, cDLBCLs presented gene 
expression signatures suggestive of MYC activation and we assessed the BET inhibitor birabresib (MK-
8628/OTX015) 10 and the BRD4 degrader MZ1 (alongside its inactive epimer cis MZ1) 11 for their capability 
to block the proliferation of the CLBL-1 12. Both drugs inhibited proliferation, although MZ1 was more 
potent (Online Supplementary Figure S9A), in accordance to data obtained in human DLBCL models 13. 
Interestingly, MZ1 significantly down-regulated not only MYC, but also LIN28B (Online Supplementary 
Figure S9B). Second, also in agreement with a transcriptome study based on a small number of canine B-
cell lymphomas 14, genes belonging to the PI3K/AKT/mTOR pathway and/or to gene expression signatures 
obtained in human DLBCL cell lines exposed to BCR inhibitors 15 were enriched in the transcripts 
expressed in cDLBCL and in the CLBL-1 (Online Supplementary Figure S10), we tested a dual 
PI3K/mTOR inhibitor bimiralisib (PQR309) and PI3K-delta inhibitor idelalisib. Both drugs were active in the 
CLBL-1 cell line with IC50 values of 150nM and 80nM, respectively (Online Supplementary Figure S9C). A 
xenograft model with CLBL-1 implanted in NOD-SCID mice showed that both bimiralisib and MZ1, given at 
the dose of 100 mg/kg, significantly affected tumor growth in comparison with the control group, with 
reduction in the tumor volume of 43% and 33% versus control on day 8 (P < 0.05) (Online Supplementary 
Figure S9D).   
In conclusion, we identified deregulated pathways and individual transcripts providing therapeutic targets, 
including an immune-related signature affecting the outcome of a subgroup of cDLBCL.  Our study 
provides a series of novel findings that allow a better understanding of cDLBCL as comparative model for 
human DLBCL but will also lead to improvements in the management of dogs in the veterinary clinical 
practice.   
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Figure legends 
 
Figure 1. Schematic representation of potential NFkB activation pathway obtained by RNA-seq 
analysis in cDLBCLs. Red, upregulated genes. Green, downregulated genes. Yellow, non-changing genes.  
 
Figure 2. Unsupervised clustering of cDLBCLs RNA-Seq data identifies groups with different outcome. 
Multidimensional scaling (MDS) plot of all the samples demonstrated a clear separation between normal B-
cells (green dots) and cDLBCLs (red dots) (a). Two cDLBCL subgroups (blue and red) were defined by 
hierarchical clustering (b). Kaplan-Meier plots of overall survival (c) and event free survival (d) of cDLBCLs 
grouped on the basis of RNA-seq profiling. Prognostic impact of PD-L1 tumor expression and PD-1 residual 
lymphocyte expression on overall survival and event free survival in cDLBCL: Kaplan-Meier plots of overall 
survival (e, g) and event free survival (f, h) based on immunohistochemical scores of PDL1 and PD1, 
respectively. 
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Online Supplementary Methods  
DLBCL cohort of primary samples 
Dogs with newly diagnosed, previously untreated, multi-centric DLBCL of any World Health 
Organization (WHO) clinical stage admitted to the Centro Oncologico Veterinario (Sasso Marconi, 
Italy) were included in the study. To be eligible for enrollment, dogs were required to undergo a 
complete staging work-up, consisting of history and physical examination, complete blood cell count 
with differential, serum biochemistry profile, thoracic radiographs and abdominal ultrasound, 
cytological evaluation of liver and spleen regardless of the ultrasonographic appearance, and 
immunophenotype determined by flow cytometry on a lymph node aspirate, peripheral blood and 
bone marrow aspirate. Before the initiation of therapy, all dogs underwent lymphadenectomy to 
confirm DLBCL histotype by routine histology and immunohistochemistry (CD3, CD20, CD79 and 
PAX5) and to provide material for the vaccine generation 1. A portion of the neoplastic lymph node 
was always RNA-later preserved and stored at -80°C. In addition to tumor samples, skin punch 
biopsies were obtained from all the dogs included in the study to provide matched paired normal 
tissue. Dogs’ owners were required to give written informed consent. Approval for this study was 
granted by the Ministero dell'Istruzione, dell'Universita' e della Ricerca Ethical Board (Number 
RBSI14EDX9).  
Dogs comprised 39 (78%) purebred and 11 (22%) crossbred dogs; among the 39 purebred dogs, 
the three more frequent were German shepherds (N 7), Golden retrievers (N 4) and Rottweiler (N 
3). There were 26 (52%) males (of which four were castrated), and 24 (48%) females (of which 15 
were spayed). The median age was 7.5 years (range 3-15 years) and the median weight was 28.9 
kg (range 4.5-81.3 kg). Based on the WHO staging system, two (4%) dogs had stage III disease, 15 
(30%) had stage IV disease, and 32 (64%) had stage V disease. Among dogs with stage V disease, 
25 (78.1%) dogs had PB and BM involvement, eight (41.2%) dogs had BM involvement, and one 
dog had PB involvement. Forty-three (86%) dogs had no symptoms at presentation (substage a), 
whereas 17 (14%) did (substage b). Twenty-six (52%) dogs had an increased LDH activity. Overall, 
14 (28%) dogs received prednisone at a dose of 0.5-1.0 mg/kg before being referred. Thirty (60%) 
dogs were treated by means of a CHOP-based protocol with the incorporation of APAVAC 
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immunotherapy, as previously described. Briefly, chemotherapy consisted of L-Asparaginase (week 
1), Vincristine (week 2, 3, 4, 13), Cyclophosphamide (week 2, 13), Doxorubicin (week 7, 16), 
Lomustine (week 10, 19), and prednisone (week 1 through 20). Dogs also received an intradermal 
injection of an autologous vaccine on weeks 4, 5, 6, 7, 12, 16, 20, and 24. Twenty (40%) dogs were 
treated with CHOP-based chemotherapy only. 
Control samples were derived from lymph nodes of 11 dogs that were clinically normal both at 
physical examination and blood profile. A portion of lymph nodes was snap frozen in O.C.T 
immediately after sampling. Five-micrometer thick frozen sections were obtained, stained with 
hematoxylin and eosin, and immunostained for CD20 and CD3 to guide the dissection. The follicular 
B-cell compartment was isolated by laser capture microdissection using the Arcturus PixCell II 
system. Both DNA and RNA were extracted as follow. 
The second independent series of 44 cDLBCLs comprised 30 (68%) purebred and 14 (32%) 
crossbred dogs; among the 30 purebred dogs, the three more frequent were Labrador retrievers (N 
8), Golden retrievers (N 5) and Dogo Argentino (N 4). There were 22 (50%) males (of which six were 
castrated), and 22 (50%) females (of which 20 were spayed). The median age was 9 years (range 
4-14 years) and the median weight was 26-7 kg (range 6.5-70.5 kg). Based on the WHO staging 
system, one (2%) dog had stage III disease, 20 (45%) had stage IV disease, and 23 (52%) had 
stage V disease. All the dogs were treated by means of a CHOP-based protocol with the 
incorporation of APAVAC immunotherapy,  
 
RNA/DNA isolation and sequencing 
Total RNA and DNA were extracted from all the samples, using the AllPrep DNA/RNA Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA concentration and 
quality were measured by Qubit fluorometer (Life Technologies Ltd, Paisley, UK) and Agarose gel 
electrophoresis.  While RNA concentration and integrity were measured in a NanoDrop ND-1000 
spectrophotometer and assessed through the Bioanalyzer 2010 instrument (Agilent Technologies, 
Palo Alto, CA, USA). 
A total of 61 non-normalized libraries for RNA sequencing experiments were prepared by using 
SureSelect Strand Specific RNA-Seq Library Preparation kit (Agilent Technologies) and a single end 
sequencing (50SE) was carried out on an Illumina HiSeq2500 (Illumina Inc., San Diego, CA, USA). 
Raw Illumina sequencing data are deposited on SRA database (GenBank) under accession 
numbers SRP137798. All Illumina reads were analyzed with FastaQC software in order to assess 
sequence quality. 
Array Comparative Genomic Hybridization 
In total, the DNA obtained from 50 cDLBCL specimens paired with normal counterpart were 
analyzed using a 180,000-feature SurePrint G3 Canine CGH Microarray (4x180K, Agilent 
Technologies), as previously described 2. Raw and normalized fluorescence data of all microarray 
experiments have been deposited in the GEO database (www.ncbi.nlm.nih.gov/geo/) under 
accession number GSE113258. 
Methyl-CpG-binding (MBD) sequencing 
Both for cDLBCLs and controls, methylated DNA was enriched by the MethylMiner Methylated DNA 
Enrichment Kit (Life Technologies) according to manufacturer’s instructions. Briefly, 2 μg of genomic 
DNA was sonicated, using Covaris S2 (Covaris, MA, USA), to obtain fragments ranging from 200 to 
600 bp in size and captured by MBD proteins. The methylated fraction of genomic DNA (100 ng) 
thus obtained was then employed to construct barcoded DNA libraries by using the TruSeq Nano 
DNA LT Library Prep Kit (Illumina Inc.) and sequenced with HiSeq2500 instrument (Illumina Inc.) 
following a 50 SE approach. Raw Illumina sequencing data are deposited on SRA database 
(GenBank) under accession numbers SRP137788. 
Immunohistochemical score 
For PD-L1 and CTLA-4, immunohistochemical scoring was recorded as the percentage of positive 
tumor cells over total tumor cells in the denominator (TPS), as reported by Roach et al. 3.  PD-L1 
expression was only considered when positive on the membrane of neoplastic lymphocytes. PD-L1 
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surface membrane expression detected on macrophages and small lymphocytes infiltrating the 
tumor was not considered. For PD-1 and CD5, tumor infiltrating lymphocytes positive labeled were 
counted using Image Pro-Plus software after low-magnification scansion of 10 representative fields 
at magnification x400. The result was expressed as the average of positive cells/x400. For statistical 
analysis a 50% cut-off TPS for PD-L1 and CTLA-4 immunohistochemical results was used. While 
for PD-1 and CD5, DLBCLs were classified as having either less than or more than 30 positive tumor 
infiltrating lymphocytes/x400 field.  
Data Mining 
RNA-Seq raw reads from library sequencing were mapped to the CanFam3.1 genome assembly 
(Broad Institute, Cambridge, MA; released Sep. 2011; downloaded from the Ensemble Genome 
Browser site) using the software tool STAR 4. Next, we obtained counts of aligned reads per gene 
using htseq-count from the HTSeq software package 5 in single-stranded mode, with canine gene 
annotations from Ensembl Release 87. Only reads that were uniquely aligned were retained. 
Differential expression analysis was performed using EdgeR. Deregulated expression of genes was 
considered as significant when p<0.05 (FDR corrected) was observed. To find sources of similarity 
in the dataset consisting of all 61 samples and the expression values of expression-filtered genes, 
multidimensional scaling (MDS) was applied. In the analysis, hierarchical clustering was used 6. The 
stability of the identified clusters was assessed using consensus clustering 7. To identify functional 
categories of differentially expressed genes, Gene Set Enrichment Analysis (GSEA) 8 was 
performed using the Java GSEA implementation. MBD-seq sequence reads were aligned to the 
CanFam3.1 genome (Ensembl Release 87) using Bowtie2 9. Quality and validity check of the 
mapped methylation-CpG binding reads was performed and high quality sequence data (MPS≥10) 
were analyzed using the MEDIPS software package to estimate methylation levels 10. We calculated 
the short read coverage (extend value=300) at genome-wide 100-bp bins. Differential methylation 
analysis was carried out in 300 bp windows excluding regions with no read coverage. Genomic 
regions with at least one consecutive window that were statistically significantly differentially 
methylated (p≤0.001) between compared samples were considered to be differentially methylated 
regions (DMRs). DMRs were annotated to the canine genome with respect to gene features using 
HOMER annotatePeaks script. If a peak had two or more annotations, a priority was assigned based 
on the order from left to right. 
Copy number variations (CNVs) data were analyzed as previously described 2. The comparison of 
transcriptomes with CNVs was done using a modified GEDI algorithm as previously described by 
Lenz et al. 11.  Deletions in Chr 26 and Chr 17, detected in 41 and 40 dogs out of 50 dogs, 
respectively, and concurrent in 33 animals, encompassed the IGLλ and IGLK genes. Deletions in 
Chr 8, seen in 35 dogs, encompassed the IGHV gene. Since these three recurrent aberrations likely 
reflected the normal immunoglobulin genes rearrangement they were discarded for further analyses. 
The impact of deletions, gains and amplifications of the selected genes on their own expression 
level was evaluated by comparing the average gene expression levels of deleted, duplicated and 
normal samples using Student’s t-test. To assess the correlation between RNA-Seq and MBD-seq, 
the correlation coefficient r was calculated and normalized to stabilize variance by applying Fisher’s 
Z-transformation 12. 
Overall survival (OS) was defined as the time from diagnosis to death. Event-free survival (EFS) 
was defined as the time from starting therapy to the date of any diagnosed relapse. Chi-square 
method was used for categorical variables and Student’s T-test for continuous variables. Survival 
was estimated with the Kaplan-Meier method and compared by log-rank tests. P values less than 
0.05 were considered statistically significant. Multivariate Cox regression analysis was used to 
assess the independent prognostic impact of different variables in terms of EFS and OS. The P 
values for multiple comparisons were adjusted using the Benjamini–Hochberg correction. Statistical 
analyses were carried out with R software v3.1.3. 
Cell lines, small interfering RNAs and cell transfection 
CLBL-1 cell line was kindly provided by Dr Barbara Rutgen (University of Wien). CLBL-1 was 
maintained in IMDM 10% FBS. Rational siRNA design was performed by Sfold, which consider 
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target accessibility and RNA duplex thermodynamics. The siRNAs were purchased from Ambion 
(Thermo Fisher Scientific) and sequences are shown in Table S8. Cells were electroporated with 
200 pmol of each siRNAs using Nucleofector in SG solution and the protocol DS142 was chosen. 
Nucleofection efficiency was checked by FACS after 24h electroporation by fluorescent labelled 
control siRNA, BLOCK IT (200 pmol). Propidium iodide was used to check cell viability. RNA was 
extracted at 24h, 48h and 72h.  
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)  
CLBL-1 total RNA was purified by phenol:chloroform extraction. RNA was also treated with DNase 
I (Qiagen) to remove genomic DNA. Quantitative RT-PCR (qRT-PCR) was performed using Qiagen 
One-Step RT-PCR kit (Qiagen) on ABI Step One Plus (Applied Biosystems) and primers for LIN28B 
and MYC indicated in Online Supplementary Table S8. qRT-PCR data were analyzed using ∆∆Ct 
and normalized. The housekeeping CCZ1 was used as reference gene 13. 
MTT proliferation assay 
CLBL-1 was exposed to increasing doses of compounds as previously described 14. Bimiralisib was 
kindly provided by Piqur Therapeutics (Basel, Switzerland), MZ1 was synthesized as previously 
described 15 and the other compounds were acquired from Selleck Chemicals (Houston, TX). Total 
RNA was extracted at different time points. 
In vivo experiment  
Fifteen NOD-Scid (NOD.CB17-Prkdcscid/NCrHsd) mice were purchased from Harlan Laboratory 
(five-six weeks of age, approximately 20 g body weight). Mice maintenance and animal experiments 
were performed under institutional guidelines established for the Animal Facility of the Institute of 
Research in Biomedicine (Bellinzona, Switzerland) and with study protocols approved by the local 
Cantonal Veterinary Authority. Mice were subcutaneously engrafted with of the canine lymphoma 
cell line CLBL-1 (10 x106 cells in 0.1mL of PBS) and divided into three experimental groups. Starting 
with an average tumor volume of 40 mm3, mice underwent treatment with bimiralisib and with MZ1 
while controls received vehicle only. Bimiralisib was prepared in 20% SBECD (sulfobutyl-ether-β-
cyclodextrin, Captisol, Dexolve) in water and pH was adjusted to 3.1. Application volume was 10 
mL/kg and mice received through oral gavage (p.o.) 100 mg/Kg of bimiralisib every day for one 
week. MZ1 was prepared in 25% HP-ß-CD [(2-Hydroxypropyl)-β-cyclodextrin; Sigma Aldrich, MO, 
USA] in water and pH was adjusted to 6.2. Application volume was 5 mL/kg and mice were injected 
intraperitoneally (i.p.) with 100 mg/Kg of MZ1 every day for one week. Tumor size was measured 
as previously described 16. 
Immunohistochemistry 
Paraffin blocks obtained by formalin fixed tumor samples were cut into 5 µm sections on superfrost 
slides. Briefly, slides were placed in 70oC paraffin oven for 1 hour before deparaffinized in xylene 
and then rehydrated in 100%, 90%, 70% alcohol, successively. Antigen was retrieved by citric acid 
buffer (pH 6.0) in the 95oC water bath for 20 minutes. Endogenous peroxidase was inactivated by 
incubation in 3% H2O2 for 15 minutes. Following a pre-incubation with 10% normal goat serum to 
block nonspecific sites for 30 minutes, the sections were incubated with primary antibodies at room 
temperature for 30 minutes (anti-bovine PD-L1 monoclonal antibody, 5A2-A1, was diluted with PBS 
at 1:100, goat polyclonal anti-PD1 antibody, ab36151, at 1:100, mouse monoclonal anti-CTLA-4, 
ANC152.2, at 1:100, and mouse monoclonal anti-CD5, YKIX322.3, at 1:50). After the sections were 
washed with PBS twice for 5 minutes, positive staining was visualized with 3-diaminobenzidine 
tetrahydrochloride (DAB) according to manufacturer’s protocol. 
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SUPPLEMENTARY TABLES 
Supplementary Table S1.  Differential expression analysis between cDLBCLs and normal lymph 
nodes. Columns A-C: Dog gene IDs (Ensembl and Entrez) and gene symbols. Column D: Gene type. 
Columns E,F: corresponding human gene IDs and gene symbols. Column G: likelihood ratio (LR) 
statistics. Column H: average logCPM (count-per-million) across all samples. Column I: logFC (Fold-
change) between cDLBCLs and normal lymph nodes.  Columns J-K: nominal and BH-adjusted (FDR) 
p-value. 
Supplementary Table S2.  Differential expression analysis between CLBL-1 cell line and normal 
lymph nodes. Columns A-C: Dog gene IDs (Ensembl and Entrez) and gene symbols. Column D: Gene 
type. Columns E,F: corresponding human gene IDs and gene symbols. Column G: likelihood ratio (LR) 
statistics. Column H: average logCPM (count-per-million) across all samples. Column I: logFC (Fold-
change) between CLBL-1 and normal lymph nodes.  Columns J-K: nominal and BH-adjusted (FDR) p-
value. 
Supplementary Table S3.  Genes found differentially expressed in chromosomal regions with 
aberrations (Gains and Losses). Columns A-B: Dog gene IDs (Ensembl) and gene symbols. Column 
C: logFC (Fold-change) between cDLBCLs and normal lymph nodes. Columns D: BH-adjusted (FDR) 
p-value. Column E: Gene type. 
Supplementary Table S4.  Regions found differentially methylated between cDLBCLs and 
normal B-cells. Table S5 contains four worksheets organized as follow: S2.1 Genomic regions 
significantly hypomethylated in cDLBCL compared to normal lymph nodes; S2.2 Gene Set Enrichment 
Analysis (GSEA) of hypomethylated genes; S2.3 Genomic regions significantly hypermethylated in 
cDLBCL compared to normal lymph nodes; S2.4 GSEA of hypermethylated genes. 
Supplementary Table S5.  Differential expression analysis between cDLBCL1 and cDLBCL2. 
Columns A-C: Dog gene IDs (Ensembl and Entrez) and gene symbols. Column D: Gene type. Columns 
E,F: corresponding human gene IDs and gene symbols. Column G: likelihood ratio (LR) statistics. 
Column H: average logCPM (count-per-million) across all samples. Column I: logFC (Fold-change) 
between cDLBCLs and normal lymph nodes.  Columns J-K: nominal and BH-adjusted (FDR) p-value. 
 
Supplementary Table S6.  Univariate and multivariate Cox regression analysis of overall 
survival for PD-L1 and PD-1 immunohistochemistry. 
 Univariate Analysis Multivariate Analysis 
 HR 95% CI P value HR 95% CI P value 
PD-L1 negative 0.446 0.234-0.765 0.006 0.505 0.274-0.956 0.036 
PD-L1 positive 1      
PD-1 negative 0.551 0.351-1.155 0.024 0.945 0.301-1.452 0.041 
PD-1 positive 1      
Age (<10 years) 0.765 0.541-1.575 0.397    
Age (>10 years) 1      
Stage (1-4) 1.542 0.884-3.553 0.145    
Stage (5) 1      
Substage a 1.753 1.054-2.563 0.021 2.405 1.309-4.794 0.011 
Substage b 1      
Bone Marrow 
Infiltration neg 
1.899 1.452-2.463 0.014 2.422 1.804-2.941 0.021 
Bone Marrow 
Infiltration pos 
1      
 
 7 
Supplementary Table S7 Sequences of siRNAs targeting LIN28B and primer sequences for 
LIN28B and MYC gene expression analysis by qRT-PCR. 
siRNA sequences 
siRNA SENSE STRAND ANTISENSE STRAND 
LIN28Bex3 GGAUUCAUCUCCAUGAUAATT UUAUCAUGGAGAUGAAUCCTT 
LIN28B ex4 UGAAUCAAUACGGGUAACUTT AGUUACCCGUAUUGAUUCATT 
LIN28B and MYC primer sequences 
PRIMER FORWARD REVERSE 
LIN28B  CCTTGGATATTCCAGTCGATGT TGGTTCTCCTTCTTTTAGGCTTCTA 
MYC TCCTCGGACTCTCTGCTCTC TCAATTTCTTCTTCGTCCTCTTG 
 
SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure S1. GSEA plots for gene-expression signatures obtained in canine 
DLBCL compared to normal B-cells. Enrichment plots of MYC-targets (a), G2M checkpoint (b), 
MTORC1 signaling (c) and BCR signaling pathway (d). Top, upregulated genes; bottom, downregulated 
genes. Green line, enrichment score; bars in the middle portion of the plots show where the members 
of the gene set appear in the ranked list of genes; Positive or negative ranking metric indicates, 
respectively, correlation or inverse correlation with the profile; NES, normalized enrichment score. 
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Supplementary Figure S2. LIN28B mRNA expression after 48h from transfection with LIN28B 
ex4 siRNA (si LIN28B ex4) compared to control (BLOCK-IT) (left panel). Cell viability after 72h from 
nucleofection with LIN28B ex4 siRNA (si LIN28B ex4) compared to control (BLOCK-IT) measured by 
MTT assay (right panel). Results are expressed as average of three independent experiments.  
 
 
 
 
 
Supplementary Figure S3. Frequency plots of DNA gains (green) and losses (red) observed in 
50 canine DLBCLs. X axis: chromosome localization and physical mapping. Y axis: percentage of 
cases bearing the aberration. 
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Supplementary Figure S4. Bar plots showing the number of differentially methylated peaks in canine 
DLBCL compared with normal B-cells. Results are reported separating peaks according to genomic 
locations. 
 
 
 
Supplementary Figure S5. Histogram and skewed distribution showing a negative correlation 
between the differences in mRNA expression and promoter methylation (skewness= -0.06, P <0.01). 
The red line represents a linear regression. 
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Supplementary Figure S6. Functional analysis of genes significantly up-regulated in DLBCL_2 
compared to DLBCL_1. A. Representative protein-protein interaction network of genes generated from 
STRING database. The connecting lines indicate functional relationships and direct protein-protein 
interactions. B. GSEA plot for gene-expression signatures obtained in DLBCL_1 compared to DLBCL_2 
and then analyzed for their enrichment in immunoinhibitory molecules as reported by Charoentong et 
al. 17. Green line, enrichment score; bars in the middle portion of the plots show where the members of 
the gene set appear in the ranked list of genes; Positive or negative ranking metric indicates, 
respectively, correlation or inverse correlation with the profile; NES, normalized enrichment score. 
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Supplementary Figure S7. Clinical, molecular and genotypic features of cDLBCLs. Tumor subgroups 
identified by RNA-seq (GX Subgroup) are indicated in salmon (DLBCL_1) and light blue (DLBCL_2) 
bars; methylation subgroups (MX Subgroup) obtained by unsupervised clustering are indicated in violet 
(group 1), red (group 2) and grey (group 3). Trisomy of chromosome 13, bone marrow (BM) infiltration, 
LDH, Overall Survival (OS) and Event Free Survival (EFS) in individual tumors are indicated. Significant 
correlation between clinical/molecular features and GX subgroups are reported on the left. 
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Supplementary Figure S8. Representative immunohistochemical analysis of PD-L1, CTLA-4, PD-1 
and CD5 expression in cDLBCL. (A) PD-L1 positive tumor cells in cDLBCL. (B) PD-L1 negative tumor 
cells in cDLBCL. (C) CTLA-4 positive tumor cells in cDLBCL. (D) CTLA-4 negative tumor cells in 
cDLBCL. (E) PD-1 lymphocytes in cDLBCL. (F) Small number of PD-1 lymphocytes in cDLBCL. (G) 
CD5 lymphocytes in cDLBCL. (H) Small number of CD5 lymphocytes in cDLBCL. 
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Supplementary Figure S9. Activity of targeted molecules on CLBL1 cell line. (a) CLBL1 cell 
line was exposed to increased doses of birabresib (OTX015/MK-8628), MZ1 or cis MZ1 for 72 hours. 
Anti-proliferative activity was evaluated by MTT assay. (b) CLBL1 cell line was treated with DMSO 
or MZ1 (500 nM) for 4 and 8 hours and expression of LIN28B (left) or MYC (right) was evaluated by 
Real Time-PCR. (c) CLBL1 cell line was exposed to increased doses of bimiralisib (PQR309) or 
idelalisib for 72 hours. Anti-proliferative activity was evaluated by MTT assay. Results are expressed 
as average of three independent experiments.  (d) NOD-SCID mice subcutaneously inoculated with 
the CLBL-1 cell line and treated with bimiralisib (n = 5), with MZ1 (n = 5) or vehicle control (CTRL, 
n = 5). Y-axis: Tumor volumes in mm3. X-axis, days post first treatment (Day 1). 
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Supplementary Figure S10. GSEA plots for gene-expression signatures obtained in cDLBCL 
compared to controls and then analyzed for their enrichment in ibrutinib target genes (top left), idelalisib 
target genes (top right), and bimiralisib (PQR309) target genes in ABC-DLBCL (bottom left) as well as 
bimiralisib target genes in GC-DLBCL (bottom right), as defined by Tarantelli et al. 16. Top, upregulated 
genes; bottom, downregulated genes. Green line, enrichment score; bars in the middle portion of the 
plots show where the members of the gene set appear in the ranked list of genes; Positive or negative 
ranking metric indicates, respectively, correlation or inverse correlation with the profile; NES, 
normalized enrichment score. 
 
 
 
 
